Sawtooth Solutions, LLC Bei Gene, Ltd. Transaction History

Sawtooth Solutions, LLC

$3.64 Billion
Q4 2023

A detailed history of Sawtooth Solutions, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Sawtooth Solutions, LLC holds 3,700 shares of BGNE stock, worth $765,234. This represents 0.02% of its overall portfolio holdings.

Number of Shares

3,700

Previous 3,828 3.34%

Holding current value

$765,234

Previous $688,000 3.05%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	SELL	$158.67 - $201.58 $20,309 - $25,802	-128 Reduced 3.34%	3,700 $667,000
Q3 2023 Oct 19, 2023	BUY	$179.87 - $225.13 $10,612 - $13,282	59 Added 1.57%	3,828 $688,000
Q2 2023 Jul 26, 2023	SELL	$178.3 - $266.78 $152,446 - $228,096	-855 Reduced 18.49%	3,769 $672,000
Q1 2023 Apr 27, 2023	BUY	$215.53 - $274.5 $236,436 - $301,126	1,097 Added 31.1%	4,624 $996,000
Q4 2022 Feb 02, 2023	BUY	$125.51 - $229.3 $25,353 - $46,318	202 Added 6.08%	3,527 $775,000
Q3 2022 Oct 12, 2022	BUY	$131.8 - $202.24 $7,380 - $11,325	56 Added 1.71%	3,325 $448,000
Q2 2022 Jul 19, 2022	BUY	$121.11 - $216.05 $395,908 - $706,267	3,269 New	3,269 $529,000
Q1 2022 May 20, 2022	SELL	$146.52 - $269.56 $359,267 - $660,961	-2,452 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $407,389 - $638,128	1,639 Added 201.6%	2,452 $664,000
Q3 2021 Nov 09, 2021	BUY	$249.6 - $403.14 $14,726 - $23,785	59 Added 7.82%	813 $295,000
Q2 2021 Sep 01, 2021	BUY	$292.75 - $367.01 $36,008 - $45,142	123 Added 19.49%	754 $259,000
Q1 2021 May 13, 2021	BUY	$260.64 - $382.12 $164,463 - $241,117	631 New	631 $220,000

Others Institutions Holding BGNE

# of Institutions

219

Shares Held

42.1M

Call Options Held

106K

Put Options Held

93.1K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $21.4B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sawtooth Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sawtooth Solutions, LLC with notifications on news.

Account

Sawtooth Solutions, LLC Bei Gene, Ltd. Transaction History